1. The effect of single doses (10, 30 and 50 mg) of a selective 5-HT2 receptor antagonist, ICI 169, 369, on blood pressure, heart rate and the electrocardiogram was studied using a double-blind, placebo-controlled, within subject design in hypertensive patients. 2. ICI 169, 369 did not reduce blood pressure or increase QT interval as has been reported with ketanserin. This suggests that it is the other properties of ketanserin which are responsible for its antihypertensive effect. 3. Plasma concentrations of AUC for ICI 169, 369 were low. This is consistent with low bioavailability due to extensive first pass metabolism. 4. ICI 169, 369 was well tolerated and none of the symptoms reported by the patients was thought to be drug related.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1379719 | PMC |
| http://dx.doi.org/10.1111/j.1365-2125.1989.tb05388.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pneumonitis after normofractionated radioimmunotherapy: a method for dosimetric evaluation.
Radiat Oncol
November 2024
Department of Radiation Oncology, School of Medicine and Klinikum rechts der Isar, Technical University of Munich (TUM), 81675, Munich, Germany.
Background: Post-Therapy-Pneumonitis (PTP) is a critical side effect of both, thoracic radio(chemo)therapy (R(C)T) and immune checkpoint inhibition (ICI). However, disease characteristics and patient-specific risk factors of PTP after combined R(C)T + ICI are less understood. Given that RT-triggered PTP is strongly dependent on the volume and dose of RT [1], driven by inflammatory mechanisms, we hypothesize that combination therapy of R(C)T with ICI influences the dose-volume-effect correlation for PTP.
View Article and Find Full Text PDFMechanism research of non-coding RNA in immune checkpoint inhibitors therapy.
Cancer Sci
November 2024
Department of Oncology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Article Synopsis
- - Immune checkpoint inhibitors (ICIs) have revolutionized tumor treatment by offering high specificity and low side effects, particularly targeting the PD-1/PD-L1 axis which plays a crucial role in how tumors evade the immune system
- - Understanding the regulatory factors affecting the PD-1/PD-L1 axis is essential for enhancing the effectiveness of ICIs and improving patient outcomes in cancer therapy
- - Non-coding RNAs (ncRNAs) have been shown to influence PD-L1 expression in the tumor immune microenvironment, thereby affecting the success of ICI therapies and highlighting their potential as targets for more effective cancer treatments
A Case of Cholangitis as a Nivolumab-Induced Immune-Related Adverse Event in a Patient with Pulmonary Metastasis After Surgery for Oral Cancer.
J Maxillofac Oral Surg
August 2024
Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575 Japan.
We report a case of cholangitis, an immune-related adverse event (irAE), caused by the administration of nivolumab in a patient with lung metastasis of oral cancer. A 72-year-old man developed pulmonary metastasis after surgery for oral cancer. Hepatic enzyme abnormalities were observed after the second session of treatment, and irAE cholangitis was diagnosed based on the results of the blood test results and endoscopy findings.
View Article and Find Full Text PDFRapid DNA methylation-based classification of pediatric brain tumors from ultrasonic aspirate specimens.
J Neurooncol
August 2024
Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Background: Although cavitating ultrasonic aspirators are commonly used in neurosurgical procedures, the suitability of ultrasonic aspirator-derived tumor material for diagnostic procedures is still controversial. Here, we explore the feasibility of using ultrasonic aspirator-resected tumor tissue to classify otherwise discarded sample material by fast DNA methylation-based analysis using low pass nanopore whole genome sequencing.
Methods: Ultrasonic aspirator-derived specimens from pediatric patients undergoing brain tumor resection were subjected to low-pass nanopore whole genome sequencing.
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.
Liver Cancer
April 2024
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy.
Article Synopsis
- Atezolizumab + bevacizumab is currently the leading treatment for advanced hepatocellular carcinoma (HCC), but there's limited direct comparison with other therapies like immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs).
- A network meta-analysis assessed various first-line systemic therapies, examining their efficacy in terms of overall survival (OS) and progression-free survival (PFS), while also considering safety profiles.
- The analysis included nine studies with 6,600 patients, finding that atezolizumab plus bevacizumab had the highest probabilities for 30-month OS, while lenvatinib excelled in PFS; ICI monotherapies were the most tolerable, and the net health
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!